Teva Pharma (TEVA) Tops Q1 EPS by 3c

Teva Pharma (NYSE: TEVA) reported Q1 EPS of $1.20, $0.03 better than the analyst estimate of $1.17. Revenue for the quarter came in at $4.81 billion versus the consensus estimate of $4.78 billion.

“We start 2016 with solid performance across the business, strong financial results and the achievement of several key milestones. Generics remains a core contributor to our performance despite no major launches in the U.S. this quarter as we had in the first quarter 2015 with continuous operational and financial improvement across the business. We finalized our acquisition of Rimsa and completed the business venture in Japan with Takeda. We continue to make important progress in our specialty business where we see great promise,” stated Erez Vigodman, President & CEO of Teva. “Looking forward, we have several upcoming approvals and key clinical milestones in our pipeline and of course the much anticipated close of Actavis Generics. We are excited to be in the final stages of completing the acquisition of Actavis Generics, which will enable us to further realize the enormous potential in the growing global generics universe and deliver the benefits of this transaction to our stockholders, customers, patients and healthcare systems around the world.”

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• Synovus Financial (SNV) PT Lowered to $42 at Piper Sandler
• Wipro (WIT) Tops Q1 EPS by 1c